EFFECTS OF HM15211, A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, ON ANTI-INFLAMMATION AND ANTI-FIBROSIS IN TAA-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSIS

被引：0

作者：

Kwon, Hyunjoo ^{[1
]}

Kim, Jung Kuk ^{[1
]}

Lee, Jong Suk ^{[1
]}

Kim, Yohan ^{[1
]}

Park, Eun Jin ^{[1
]}

Choi, Jaehyuk ^{[2
]}

Bae, Sung Min ^{[1
]}

Kim, Dae Jin ^{[1
]}

Lee, Sang Hyun ^{[1
]}

Choi, In Young ^{[1
]}

机构：

[1] Hanmi Pharm Co Ltd, Seoul, South Korea

[2] 14 Wiryeseong Daero, Wiryeseong Daero, South Korea

来源：

HEPATOLOGY | 2022年 / 76卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2453

引用

页码：S716 / S717

页数：2

共 50 条

[31] Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/fibrosis
Lee, Jong Suk
Kim, Jung Kuk
Lee, Seonmyeong
Kim, Yohan
Choi, Jaehyuk
Kwon, Hyunjoo
Park, Eun Jin
Bae, Sung Min
Lee, Sang Hyun
Choi, In Young
JOURNAL OF HEPATOLOGY, 2022, 77 : S468 - S469
[32] Potential effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical model of cholestatic liver disease
Kim, Jung Kuk
Lee, Jong Suk
Kim, Yohan
Choi, Jae Hyuk
Kwon, Hyunjoo
Park, Eun Jin
Lee, Jong Soo
Bae, Sung Min
Lee, Sang Hyun
Choi, In Young
JOURNAL OF HEPATOLOGY, 2021, 75 : S417 - S417
[33] Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF
Kim, Jeong A.
Lee, Jong Suk
Kim, Jung Kuk
Ban, Young-Hwan
Lee, Jongsoo
Bae, Sungmin
Kim, Daejin
Lee, Sang Hyun
Choi, In Young
DIABETES, 2022, 71
[34] Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis
Kim, Jung Kuk
Kim, Yohan
Lee, Jong Suk
Kwon, Hyunjoo
Park, Eun Jin
Kim, Jeong A.
Bae, Sung Min
Kim, Dae Jin
Lee, Sang Hyun
Choi, In Young
JOURNAL OF HEPATOLOGY, 2023, 78 : S758 - S758
[35] ANTI-INFLAMMATORY AND ANTI-FIBROTIC EFFECTS BY SIMULTANEOUS ACTIVATION OF GLUCAGON, GIP, AND GLP-1 OF EFOCIPEGTRUTIDE (HM15211) IN THIOACETAMIDE-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSIS
Kim, Jung Kuk
Kim, Yohan
Kwon, Hyunjoo
Park, Eun Jin
Kim, Jeong A.
Park, Sang Hyun
Bae, Sungmin
Kim, Daejin
Lee, Sang Hyun
Choi, In Young
HEPATOLOGY, 2023, 78 : S1192 - S1193
[36] Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in animal model of NASH
Choi, J.
Lee, J.
Kim, J.
Kwon, H.
Park, E.
Lee, J.
Kim, D.
Kim, Y.
Choi, I.
DIABETOLOGIA, 2021, 64 (SUPPL 1) : 100 - 101
[37] Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/Glucagon/GIP Tri-Agonist in the MPTP Parkinson's Disease Mouse Model
Lee, Young Mi
Lee, Sang Hyun
Kim, Jeong A.
Choi, In Young
Kim, Young Hoon
Kwon, Se Chang
DIABETES, 2017, 66 : A303 - A303
[38] Neuroprotective effects of HM15211, a novel long-acting GLP-1/Glucagon/GIP tri-agonist in the MPTP Parkinson's disease mouse model
Lee, Y.
Lee, S. -H.
Kim, J.
Choi, I.
Kim, Y.
Kwon, S.
DIABETOLOGIA, 2017, 60 : S579 - S579
[39] Study on multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH
Lee, Jong Suk
Kim, Jung Kuk
Lee, Seon Myeong
Choi, Jae Hyuk
Kwon, Hyunjoo
Park, Eun Jin
Lee, Jong Soo
Kim, Dae Jin
Lee, Sang Hyun
Choi, In Young
JOURNAL OF HEPATOLOGY, 2021, 75 : S615 - S615
[40] STUDY ON MULTI-TARGET ENGAGEMENT EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, HM15211, IN ANIMAL MODEL OF NASH
Lee, Jong Suk
Kim, Jung Kuk
Lee, Seon Myeong
Choi, Jaehyuk
Kwon, Hyunjoo
Park, Eun Jin
Lee, Jong Soo
Kim, Dae Jin
Lee, Sang Hyun
Choi, In Young
HEPATOLOGY, 2021, 74 : 1088A - 1089A

← 1 2 3 4 5 →